# Single Source: AIDS and Cancer Specimen Resource (ACSR; UM1 Clinical Trials Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-ca-23-043-single-source-aids-and-cancer-specimen-resource-acsr/  
Official notice: https://www.grants.gov/search-results-detail/350843

> National Institutes of Health offered grants to small businesses. Applications closed on January 9, 2024.

| Field | Value |
|---|---|
| Opportunity number | RFA-CA-23-043 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | January 9, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.393, 93.394, 93.395, 93.396, 93.399 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. See full Notice of Funding Opportunity for additional details on eligibility.

## What the grant funds

Through this non-competitive single source cooperative agreement Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits an application from (-----institute name-----) with the intent of funding a single award to continue to support the AIDS and Cancer Specimen Resource (ACSR). This is a reissue of RFA-CA-18-012. The ACSRs mission is to address the specimen needs of clinician and basic researchers in HIV and HIV-associated malignancy research. The ACSR is an international repository with specimens that reflect different eras of the epidemic (notably pre-cART and post-cART), different regions of the world, and people of diverse genetic backgrounds with different environmental exposures. Specimens have been obtained from people with HIV (PWH), people at risk for acquiring HIV, and HIV-uninfected controls. Specimens have been obtained from participants in clinical trials, observational cohort studies, or other research studies conducted by HIV investigators and consortium. The ACSR uses informed approaches to prospectively curate specimens in the USA, sub-Saharan Africa and Latin America that will be most valuable for the research community. Specimens and associated data are made available to the research community-at-large at NO COST. A second key role of the ACSR, is to serve as the AMC Biorepository for the AIDS Malignancy Consortium (AMC). The AMC is an NCI funded, multicenter clinical trials cooperative group that performs clinical trials research in the treatment and prevention of HIV-associated malignancies. The ACSR is currently providing support for domestic (two), sub-Saharan African, and Latin American biorepositories for the AMC.

## Questions people ask

### Is RFA-CA-23-043 still open?

No. It closed on January 9, 2024.

### Who can apply for Single Source: AIDS and Cancer Specimen Resource (ACSR; UM1 Clinical Trials Not Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Single Source: AIDS and Cancer Specimen Resource (ACSR; UM1 Clinical Trials Not Allowed)?

Closed January 9, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has won Cancer Cause and Prevention Research grants before?

The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.